================================================================================
PHARMACY SALES PRESCRIPTIVE RECOMMENDATIONS (IMPROVED)
Generated: 2025-10-24 00:19:34
================================================================================

üì¶ INVENTORY MANAGEMENT RECOMMENDATIONS:

  ‚úì HIGH PRIORITY REORDERS (Top 5 by demand):
    ‚Ä¢ NOVASARTAN (LOSARTAN K) 50MG FC TAB: Reorder at 396 units
      - Safety stock: 207 units | 30-day forecast: 831 units
    ‚Ä¢ GOZTAN-50 (LOSARTAN POTASSIUM) 50MG TAB: Reorder at 263 units
      - Safety stock: 141 units | 30-day forecast: 262 units
    ‚Ä¢ CETIRILIFE (CETIRIZINE) 10MG TAB: Reorder at 307 units
      - Safety stock: 188 units | 30-day forecast: 1034 units
    ‚Ä¢ BIOGESIC 500MG TAB: Reorder at 175 units
      - Safety stock: 76 units | 30-day forecast: 211 units
    ‚Ä¢ OHHIRA&#039;S RED OMX PROBIOTICS CAP: Reorder at 127 units
      - Safety stock: 53 units | 30-day forecast: 160 units

üìã ORDERING STRATEGY RECOMMENDATIONS:

  ‚úì OPTIMAL ORDER QUANTITIES (Top 5):
    ‚Ä¢ NOVASARTAN (LOSARTAN K) 50MG FC TAB: Order 1274 units every 145 days
    ‚Ä¢ MULTICAPS: Order 1342 units every 163 days
    ‚Ä¢ APPEVIT (BUCLIZINE HCL+B-COMPLEX+IRON) CAP: Order 400 units every 76 days
    ‚Ä¢ BIOGESIC (PARACETAMOL) 500MG TAB: Order 735 units every 142 days
    ‚Ä¢ GOZTAN-50 (LOSARTAN POTASSIUM) 50MG TAB: Order 929 units every 252 days

üí∞ BUDGET ALLOCATION RECOMMENDATIONS:

  ‚úì PRIORITIZE INVESTMENT IN:
    ‚Ä¢ MULTICAPS: 102510 units (‚Ç±205,020.80)

üíµ PRICING & DISCOUNT RECOMMENDATIONS:

  ‚úì MAINTAIN/INCREASE DISCOUNTS FOR:
    ‚Ä¢ MULTICAPS: 0.0% discount (efficiency: 14999.9)
    ‚Ä¢ LIVERAIDE (SILYMARIN) CAP: 0.0% discount (efficiency: 1800.0)
    ‚Ä¢ NEOFORM 500MG TAB: 0.0% discount (efficiency: 1000.0)

üìà SALES GROWTH OPPORTUNITIES:

  ‚úì PROMOTE HIGH-MARGIN PRODUCTS:
    ‚Ä¢ #EXP2027-05-24: 100.0% margin
    ‚Ä¢ ALCIFLORA (BACILLUS CLAUSII) 5ML: 100.0% margin
    ‚Ä¢ ATORMED -20 (ATORVASTATIN) 20MG TAB: 100.0% margin
    ‚Ä¢ AUGMENTIN (CO-AMOXICLAV) 1G: 100.0% margin
    ‚Ä¢ AZIMED (AZITHROMYCIN) 500MG: 100.0% margin

‚öôÔ∏è OPERATIONAL EFFICIENCY:

  ‚úì INVESTIGATE 31 ANOMALOUS SALES DAYS
    ‚Ä¢ 2023-02-14: ‚Ç±77,845.62 (Score: -0.77)
    ‚Ä¢ 2025-03-05: ‚Ç±31,407.28 (Score: -0.74)
    ‚Ä¢ 2025-03-08: ‚Ç±54,333.68 (Score: -0.70)

üèóÔ∏è RESOURCE PLANNING (Next 90 Days):

  ‚úì PREPARE FOR NEXT QUARTER:
    ‚Ä¢ Storage needed: 16,897 cubic feet
    ‚Ä¢ Capital required: ‚Ç±247,456.17